Citations

Showing 10 of 108104 citations.

Standardized Versus Tailored Implementation of Measurement-Based Care for Depression in Community Mental Health Clinics
Lewis, Cara C. , Marti, C. Nathan , Scott, Kelli , Walker, Madison R. , Boyd, Meredith R. , Puspitasari, Ajeng J. , Mendel, Peter , Boyd, Meredith, Puspitasari, Ajeng, Lewis, Cara C , Kroenke, Kurt

Mayo Clinic

Psychiatric Services | May 11, 2022 | Volume: 73 | Issue: 10 | Pages: 1094-1101

10.1176/appi.ps.202100284 | PMID 35538748 Get It

Influence of surgical technique in donor hepatectomy on immediate and short‐term living donor outcomes – A systematic review of the literature, meta‐analysis, and expert panel recommendations
Cheah, Yee Lee , Kwon, Choon Hyuck David , Pomposelli, James J. , Rudow, Dianne LaPointe , Bröering, Dieter C. , Spiro, Michael , Roberts, John P. , Group, the ERAS4OLT.org Working, Rudow, Dianne LaPointe , Roberts, John P , Heimbach, Julie K. , Raptis, Dimitri , Group, the ERAS4OLT.org Working, Tinguely, Pascale

Mayo Clinic

Clinical Transplantation | May 11, 2022 | Volume: 36 | Issue: 10 | Pages: No page available

10.1111/ctr.14703 | PMID 35538019 Get It

AbstractBackgroundThere are currently no guidelines pertaining to ERAS pathways in living donor hepatectomy.ObjectivesThe aim of this study was to identify whether surgical technique influences immediate and short‐term outcomes after living liver donation surgery.Data sourcesOvid MEDLINE, Embase, Scopus, Google Scholar, and Cochrane Central.MethodsSystematic review and meta‐analysis following PRISMA guidelines and recommendations using the GRADE approach derived from an international expert panel (CRD42021260707). Endpoints were mortality, overall complications, serious complications, bile eaks, pulmonary complications, estimated blood loss and length of stay.ResultsOf the 2410 screened articles, 21 articles were included for final analysis; three observational, 13 retrospective cohort, four prospective cohort studies, and one randomized trial. Overall complications were higher with right versus left hepatectomy (26.8% vs. 20.8%; OR 1.4, P = .010). Donors after left hepatectomy had shorter length of stay (MD 1.4 days) compared to right hepatectomy. There was no difference in outcomes after right donor hepatectomy with versus without middle hepatic vein. We had limited data on the influence of incision type and minimally invasive approaches on living donor outcomes, and no data on the effect of operative time on donor outcomes.ConclusionsLeft donor hepatectomy should be preferred over right hepatectomy, as it is related to improved donor short‐term outcomes (QOE; Moderate | Grade of Recommendation; Strong). Right donor hepatectomy with or without MHV has equivalent outcomes (QOE; Moderate | Grade of Recommendation; Strong); no preference is recommended, decision should be based on program's experience and expertise. No difference in outcomes was observed related to incision type, minimally invasive vs. open (QOE; Low | Grade of Recommendation; Weak); no preference can be recommended.
Cannabidiol for Functional Dyspepsia With Normal Gastric Emptying: A Randomized Controlled Trial
Atieh, Jessica , Maselli, Daniel B. , Breen‐Lyles, Margaret K., Torres, Monique, Katzka, David A. , Ryks, Michael, Busciglio, Irene, Burton, Duane D. , Carlson, Paula, Harmsen, William S. , Camilleri, Michael , Maselli, Daniel, Breen-Lyles, Margaret, Katzka, David, Burton, Duane

Mayo Clinic

American Journal of Gastroenterology | May 10, 2022 | Volume: 117 | Issue: 8 | Pages: 1296-1304

10.14309/ajg.0000000000001805 | PMID 35537858 Get It

INTRODUCTION: Cannabidiol (CBD), a CBR2 agonist with limited psychic effects, antagonizes CB1/CB2 receptors. Allelic variation CNR1 (gene for CBR1) rs806378 and FAAH rs324420 were associated with altered gut motility and sensation. This study aimed to compare the pharmacodynamics and clinical effects of a 4-week treatment with pharmaceutical-grade CBD vs placebo and assess the interactions of FAAH and CNR1 gene variants on the effects of CBD in patients with functional dyspepsia (FD). METHODS: We performed a randomized, double-blinded, placebo-controlled (1:1 ratio) study of CBD b.i.d. (20 mg/kg/d according to the US Food and Drug Administration escalation guidance) in FD patients with nondelayed gastric emptying (GE) at baseline. Symptoms were assessed by validated daily symptom diary (0–4 scale for upper abdominal pain, nausea, and bloating), weekly assessment of adequate relief, Leuven Postprandial Distress Scale (8 symptoms, adjectival scores rated 0–4 for severity), and quality of life (Short-Form Nepean Dyspepsia Index [average of 10 dimensions each on a 5-point scale]). After the 4-week treatment, all patients underwent measurements of GE of solids, gastric volumes, and Ensure nutrient satiation test. Statistical analysis compared 2 treatments for all endpoints and the effects of CBD in association with FAAH rs324420 and CNR1 rs806378. RESULTS: CBD and placebo effects on physiological functions and patient response outcomes were not significantly different. There were borderline CBD treatment-by-genotype interactions: rs806378 CNR1 with Leuven Postprandial Distress Scale ( P = 0.06) and GE solids ( P = 0.12). DISCUSSION: Approved doses of CBD used off-label do not relieve FD with normal baseline GE of solids or alter gastric motor functions and satiation. CBD treatment-by-gene interactions suggest potential benefits for postprandial distress with CNR1 rs806378 T allele.
CPI Emergency Imaging Module 2020
Brooks, Michael K., Choi, Andrew Y., Kubal, Wayne S., Mazzie, Joseph P., Menias, Christine A., Milla, Sarah Sarvis , Moshiri, Mariam , Nuñez, Diego , Raptis, Constantine A. , Roberts, Matthew S., Bhalla, Sanjeev , Cohen, Harris L. , Mellnick, Vincent M. , Patlas, Michael N.

Mayo Clinic

Continuous Professional Improvement | May 10, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.54057/cpi.er2020 Get It

Stabilizing the pharmacy technician workforce as an imperative for the chief pharmacy officer
Rewald, Matthew, Woller, Thomas W., Sullivan, Mark P., Sullivan, Mark

Mayo Clinic

American Journal of Health-System Pharmacy | May 10, 2022 | Volume: 79 | Issue: 17 | Pages: 1445-1448

10.1093/ajhp/zxac135 | PMID 35536741 Get It

Patient Engagement in Urological Research: A Call to Action
Tyson, Mark D. , Siemens, D. Robert

Mayo Clinic

Journal of Urology | May 10, 2022 | Volume: 208 | Issue: 2 | Pages: 241-242

10.1097/ju.0000000000002762 | PMID 35536672 Get It

Targeted temperature management after out of hospital cardiac arrest: quo vadis?
Hansen, Carolina Malta , Hassager, Christian , Jentzer, Jacob C. , Menon, Venu , Perman, Sarah M. , Diepen, Sean van , Granger, Christopher B. , Krychtiuk, Konstantin A , Jentzer, Jacob C , van Diepen, Sean , Granger, Christopher B , Hassager, Christian , Fordyce, Christopher B.

Mayo Clinic

European Heart Journal. Acute Cardiovascular Care | May 10, 2022 | Volume: 11 | Issue: 6 | Pages: 512-521

10.1093/ehjacc/zuac054 | PMID 35579006 Get It

AbstractTargeted temperature management (TTM) has become a cornerstone in the treatment of comatose post-cardiac arrest patients over the last two decades. Belief in the efficacy of this intervention for improving neurologically intact survival was based on two trials from 2002, one truly randomized-controlled and one small quasi-randomized trial, without clear confirmation of that finding. Subsequent large randomized trials reported no difference in outcomes between TTM at 33 vs. 36°C and no benefit of TTM at 33°C as compared with fever control alone. Given that these results may help shape post-cardiac arrest patient care, we sought to review the history and rationale as well as trial evidence for TTM, critically review the TTM2 trial, and highlight gaps in knowledge and research needs for the future. Finally, we provide contemporary guidance for the use of TTM in daily clinical practice.
Peri-intubation Cardiovascular Collapse in Patients Who Are Critically Ill: Insights from the INTUBE Study
Russotto, Vincenzo , Parotto, Matteo , Bauer, Philippe R. , Camporota, Luigi , Putensen, Christian , Higgs, A. , Pesenti, Antonio, Valsecchi, Maria Grazia , Fumagalli, Roberto , Laffey, John G. , Brewster, David , Mazlan, Mohd Zulfakar , Rahmani, Lua S. , Bauer, Philippe R , Bellani, Giacomo , Laffey, John G , Lascarrou, Jean-Baptiste , Tassistro, Elena , Myatra, Sheila Nainan , Antolini, Laura , Szuldrzynski, Konstanty S. , Pelosi, Paolo , Sorbello, Massimiliano , Greif, Robert , Pesenti, Antonio, Foti, Giuseppe

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 10, 2022 | Volume: 206 | Issue: 4 | Pages: 449-458

10.1164/rccm.202111-2575oc | PMID 35536310 Get It

Abstract Rationale Cardiovascular instability/collapse is a common peri-intubation event in patients who are critically ill. Objectives To identify potentially modifiable variables associated with peri-intubation cardiovascular instability/collapse (i.e., systolic arterial pressure <65 mm Hg [once] or <90 mm Hg for >30 minutes; new/increased vasopressor requirement; fluid bolus >15 ml/kg, or cardiac arrest). Methods INTUBE (International Observational Study to Understand the Impact and Best Practices of Airway Management In Critically Ill Patients) was a multicenter prospective cohort study of patients who were critically ill and undergoing tracheal intubation in a convenience sample of 197 sites from 29 countries across five continents from October 1, 2018, to July 31, 2019. Measurements and Main Results A total of 2,760 patients were included in this analysis. Peri-intubation cardiovascular instability/collapse occurred in 1,199 out of 2,760 patients (43.4%). Variables associated with this event were older age (odds ratio [OR], 1.02; 95% confidence interval [CI], 1.02–1.03), higher heart rate (OR, 1.008; 95% CI, 1.004–1.012), lower systolic blood pressure (OR, 0.98; 95% CI, 0.98–0.99), lower oxygen saturation as measured by pulse oximetry/Fi O2 before induction (OR, 0.998; 95% CI, 0.997–0.999), and the use of propofol as an induction agent (OR, 1.28; 95% CI, 1.05–1.57). Patients with peri-intubation cardiovascular instability/collapse were at a higher risk of ICU mortality with an adjusted OR of 2.47 (95% CI, 1.72–3.55), P < 0.001. The inverse probability of treatment weighting method identified the use of propofol as the only factor independently associated with cardiovascular instability/collapse (OR, 1.23; 95% CI, 1.02–1.49). When administered before induction, vasopressors (OR, 1.33; 95% CI, 0.84–2.11) or fluid boluses (OR, 1.17; 95% CI, 0.96–1.44) did not reduce the incidence of cardiovascular instability/collapse. Conclusions Peri-intubation cardiovascular instability/collapse was associated with an increased risk of both ICU and 28-day mortality. The use of propofol for induction was identified as a modifiable intervention significantly associated with cardiovascular instability/collapse. Clinical trial registered with clinicaltrials.gov (NCT03616054).
Clinical and microbiologic outcomes of central nervous system cryptococcosis: Re‐examining the need for a 2‐week cerebrospinal fluid analysis
Yetmar, Zachary A. , Mendoza, Maria A. , Yetmar, Zachary A , Ranganath, Nischal , Razonable, Raymund R.

Mayo Clinic

Mycoses | May 10, 2022 | Volume: 65 | Issue: 7 | Pages: 733-740

10.1111/myc.13467 | PMID 35535694 Get It

AbstractBackgroundCryptococcus spp. infection involving the central nervous system (CNS) is associated with poor outcomes. Current guidelines recommend repeating a cerebrospinal fluid (CSF) fungal culture after 2 weeks of treatment to evaluate for clearance. However, this practice has not clearly been associated with outcomes.ObjectivesWe sought to assess the relationship between CSF fungal clearance at 2 weeks and 12‐month mortality in patients with CNS cryptococcosis.MethodsThis is a retrospective cohort study from 2011 to 2020 of patients with CNS cryptococcosis. Factors associated with 12‐month mortality were assessed with Fisher’s exact test for categorical variables and Mann–Whitney test for continuous variables.ResultsAmong 51 patients with CNS cryptococcosis, 42 (82.4%) were initially CSF culture positive. Among 27 patients with follow‐up CSF culture at 2 weeks, 6 (22.2%) had a positive result. Factors associated with a positive CSF culture at 2 weeks were an initial CSF cryptococcal antigen titre ≥1:2560, fungaemia, and an elevated intracranial pressure requiring therapeutic lumbar punctures. The 12‐month mortality rate was 33.3%, and this was significantly associated with baseline fungaemia, extra‐CNS cryptococcal involvement and requirement of intensive care unit level of care. Lack of CSF culture clearance by 2 weeks was not associated with 12‐month mortality.ConclusionsCNS cryptococcosis has a high mortality rate. A markedly elevated CSF cryptococcal antigen, and opening CSF pressure was associated with lack of CSF culture clearance at 2 weeks of treatment. Severe disseminated disease and cryptococcemia were associated with 12‐month mortality.